NCT03055013 2026-03-17
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT00715442 2025-12-23
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT07226544 2025-11-10
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT00930033 2025-09-05
CARMENA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT06882486 2025-03-18
NAMECAR
Institut Paoli-Calmettes
Phase NA Not yet recruiting
NCT03473730 2025-01-30
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT05024318 2024-05-16
NAPSTER
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT04570176 2022-02-16
Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System
The Affiliated Hospital of Qingdao University
Phase NA Completed
NCT03189186 2021-04-05
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
Phase 1 Withdrawn
NCT02595918 2020-10-23
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02170389 2020-07-07
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Roswell Park Cancer Institute
Phase NA Terminated
NCT01070186 2012-07-31
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn